Surgery Partners Raises Buyout Price to $25 Per Share in Amended Merger Deal
Surgery Partners (SGRY) amended its merger deal with Spyglass Topco, raising the buyout price to $25 per share. If the deal isn't closed by March 1, 2027, shareholders will receive monthly payments at a 10% annual rate, up to $1.61 per share by the October 23, 2027 deadline. The termination fee increased to approximately $149.1 million.
How this was made
The 30-second read
Why it matters
The amendment increases the cash acquisition price and adds a sizable termination fee, likely boosting the stock price.
Market read
Fresh merger amendment provides new pricing information, creating a clear trading catalyst.
What to watch
Potential regulatory hurdles and financing costs for the increased cash consideration.
Background
Surgery Partners announced an amendment to its pending merger with Spyglass Topco, an affiliate of Bon Secours Mercy Health.
Ticker impact
Amended merger agreement raises cash price to $25 per share and adds a $149.1M termination fee.
upward pressure as market prices in the increased buyout premium.
The amendment is a fresh, material disclosure that directly raises the valuation of Surgery Partners.
Market effects
Potential ripple in the healthcare services M&A space as higher premiums may set new benchmarks.
U.S. healthcare sector may see modest uplift.
Limited to U.S. listed healthcare providers.
Counterpoint
Higher price could signal buyer's urgency, but also raises integration risk and may overpay.
Key entities
- companySurgery Partners, Inc.
Target company in the merger.
- companySpyglass Topco
Acquiring affiliate of Bon Secours Mercy Health.
